Title: Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors
Authors: Brouckaert, Olivier ×
Pintens, Saskia
Van Belle, Vanya
Van Huffel, Sabine
Camerlynck, Edward
Amant, Frédéric
Smeets, Ann
Leunen, Karin
Van Limbergen, Erik
Berteloot, Patrick
Hendrickx, Wouter
Decock, Julie
Weltens, Caroline
Van den Bogaert, Walter
Vanden Bempt, Isabelle
Paridaens, Robert
Drijkoningen, Maria
Wildiers, Hans
Vergote, Ignace
Christiaens, Marie-Rose
Neven, Patrick #
Issue Date: May-2009
Publisher: M. Nijhoff
Series Title: Breast Cancer Research and Treatment vol:115 issue:2 pages:349-358
Abstract: Introduction Prognostic subgroup classification of operable breast cancers using cDNA clustering of breast cancer-related genes resembles the classification based on the combined immunohistochemical (IHC) expression of the hormone and HER-2 receptors. We here report the short-term disease-free interval (DFI) of operable breast cancers by their joint hormone receptor/HER-2 phenotype. Patients and methods Short-term follow-up (FU) of a prospective cohort of 1,958 breast-cancer patients primary operated at our institution between 2000 and 2005. Receptors were evaluated using IHC. Steroid receptors were considered positive for any nuclear staining; HER-2 for strong (3+) membrane staining or positive fluorescence in situ hybridization (FISH). Kaplan-Meier (KM) DFI curves were calculated for any relapse defined as a local, regional, contralateral, or distant breast cancer event for the six predefined breast cancer subgroups: ER + PR + HER-2 - (PPN), ER + PR - HER-2 - (PNN), ER + PR + HER-2 + (PPP), ER - PR - HER-2 - (NNN), ER - PR - HER-2 + (NNP), and ER + PR - HER-2 + (PNP). P-values were calculated for comparison of the six different survival curves using two possible adaptations for multiple testing. A multivariate model for the receptors predicting DFI did incorporate local and systemic adjuvant therapy. Results Median patient age was 57 years (ranges 26-96) and median FU was 3.35 years. Overall, DFI at median FU was 91%; 94% for PPN, 89% for PNN, 86% for NNN, 81% for PPP, 80% for PNP, and 76% for NNP cases. Some receptor subgroups had a significantly better DFI than others based on multiple testing, especially when the PPN group was compared against the four most frequent subtypes. The multivariate model with local and systemic adjuvant therapy confirmed the prognostic value of ER, PR, and HER-2 for short-term DFI. Conclusion It is possible to distinguish short-term prognostic breast cancer subgroups only on the basis of ER, PR, and HER-2 even when stratified for local and systemic adjuvant therapy. While gene expression profiles based on microarray data of over hundreds of genes will probably teach us much about breast cancer biology, heterogeneity, and prognosis, we emphasize the important short-term prognostic value of currently used IHC markers for ER, PR, and HER-2.
ISSN: 0167-6806
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Translational Cell & Tissue Research
Laboratory of Experimental Radiotherapy
Section Woman - Miscellaneous (-)
Multidisciplinary Breast Clinic Section (-)
ESAT - STADIUS, Stadius Centre for Dynamical Systems, Signal Processing and Data Analytics
Gynaecological Oncology
Laboratory of Experimental Oncology
Surgical Oncology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.pdf Published 288KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science